UroGen Pharma Yönetim
Yönetim kriter kontrolleri 3/4
UroGen Pharma CEO'su Liz Barrett, Jan2019 tarihinde atandı, in görev süresi 7.33 yıldır. in toplam yıllık tazminatı $ 4.31M olup, şirket hissesi ve opsiyonları dahil olmak üzere 19.8% maaş ve 80.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.67% ine doğrudan sahiptir ve bu hisseler $ 9.76M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6 yıl ve 7.3 yıldır.
Anahtar bilgiler
Liz Barrett
İcra Kurulu Başkanı
US$4.3m
Toplam tazminat
| CEO maaş yüzdesi | 19.85% |
| CEO görev süresi | 7.3yrs |
| CEO sahipliği | 0.7% |
| Yönetim ortalama görev süresi | 6yrs |
| Yönetim Kurulu ortalama görev süresi | 7.3yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • May 21
URGN: Future Regulatory And Funding Setbacks Will Likely Restrain Upside Potential
Narrative Update on UroGen Pharma The updated analyst price target for UroGen Pharma has shifted from about $19.68 to roughly $20.86 as analysts incorporate recent initiations and target increases, including the $5 and $6 target hikes and renewed Buy views, into their valuation work. Analyst Commentary Recent research on UroGen Pharma has leaned constructive, with several firms initiating or reaffirming Buy views and lifting their price targets.Seeking Alpha • May 07
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
Summary UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue. Risks include execution on Zusduri adoption, debt burden, and long-term generic threats, but current sales momentum and operating leverage support the bullish thesis. Read the full article on Seeking AlphaAnlatı Güncellemesi • May 03
URGN: Future Regulatory And Cost Setbacks Will Likely Restrain Upside Potential
Analysts have raised their price target on UroGen Pharma from $16.57 to $19.68 as updated assumptions for revenue growth, profit margins and a lower future P/E multiple align with a recently initiated bullish view on the stock. Analyst Commentary Recent research commentary on UroGen Pharma reflects a bullish initiation that aligns with the higher price target.
Anlatı Güncellemesi • Apr 18
URGN: Future Profit Margins Will Improve Through LG UTUC Trial Momentum
Analysts have nudged their price target for UroGen Pharma higher to $36.11 from $35.63, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E following recent bullish Street research coverage. Analyst Commentary Recent Street research on UroGen Pharma has leaned constructive, which feeds into the modest uptick in the blended price target to $36.11.Anlatı Güncellemesi • Apr 03
URGN: Future Profit Margins Will Improve Through New J Code Reimbursement
Analysts have modestly fine-tuned their price target framework for UroGen Pharma, keeping fair value around $35.63. Small adjustments to the discount rate, revenue growth, profit margin, and forward P/E reflect updated assumptions rather than a major change in outlook.Anlatı Güncellemesi • Mar 20
URGN: Future Profit Margins Will Benefit From New J Code And Loan Refinancing
Analysts kept their fair value estimate for UroGen Pharma steady at $35.63 while making only minimal adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E. These changes reflect updated views on operating costs and financing conditions, similar to those that recently led to modest target reductions in other healthcare names.Anlatı Güncellemesi • Mar 05
URGN: Future Profit Margins Will Benefit From New J Code Reimbursement
Analysts now place UroGen Pharma's fair value at about $35.63, compared with the prior $35.25. This reflects updated assumptions around a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a higher future P/E estimate.Analiz Makalesi • Dec 05
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders have had their patience rewarded with a 26% share price jump in the...Anlatı Güncellemesi • Nov 26
URGN: Future Profit Margins Will Benefit From Recent Regulatory Milestones
Analysts have raised their price target for UroGen Pharma from $33.75 to $35.25. They cite expectations of stronger revenue growth and improved profit margins as key drivers for the increase.Analiz Makalesi • Oct 06
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues
It's not a stretch to say that UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 8.5x right now...Anlatı Güncellemesi • Sep 09
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Driven by an improved net profit margin and a modest reduction in future P/E, analysts have raised UroGen Pharma’s consensus price target from $32.00 to $33.75. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only approved therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Anlatı Güncellemesi • Aug 15
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
As there is no change in the key metrics—consensus price target ($31.43), discount rate (6.85%), and future P/E (15.67x)—analyst valuation for UroGen Pharma remains steady, reflecting an unchanged fair value. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Analiz Makalesi • Aug 10
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
NasdaqGM:URGN 1 Year Share Price vs Fair Value Explore UroGen Pharma's Fair Values from the Community and select yours...Analiz Makalesi • Jul 07
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • May 17
Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop
The UroGen Pharma Ltd. ( NASDAQ:URGN ) share price has fared very poorly over the last month, falling by a substantial...Analiz Makalesi • May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
It's shaping up to be a tough period for UroGen Pharma Ltd. ( NASDAQ:URGN ), which a week ago released some...Yeni Anlatı • May 07
UGN-102 Approval Will Broaden Bladder Cancer Treatment Options
Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.Analiz Makalesi • Feb 12
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 4.8x UroGen Pharma Ltd. ( NASDAQ:URGN ) is definitely a...Seeking Alpha • Jan 31
UroGen: Upcoming PDUFA, Some Concerns Remain
Summary UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk NMIBC, with significant clinical trial success and a PDUFA date set for June 13, 2025. Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap suggests caution; a pilot investment is recommended with awareness of associated risks. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 28
UroGen Pharma: There Is Some Potential Here
Summary UroGen Pharma Ltd. focuses on urothelial and specialty cancers, with Jelmyto approved for LG-UTUC and promising pipeline candidates like UGN-102 for bladder cancer. UGN-102 should garner FDA approval in the first half of 2025 and has a much bigger potential market than Jelmyto. UroGen is also advancing some next-generation candidates within its pipeline and has adequate near-term funding in place. An analysis around UroGen Pharma follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 17
UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Summary ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potential for priority review. UroGen Pharma's blockbuster drug potential, liquidity, and modest market cap make it a strong buy. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Analiz Makalesi • Apr 09
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
UroGen Pharma Ltd. ( NASDAQ:URGN ) shares have had a horrible month, losing 27% after a relatively good period...Seeking Alpha • Mar 18
UroGen: All Eyes On UGN-102
Summary JELMYTO revenues are growing but not by enough to support UroGen's operations. Guided financials show ongoing losses with adequate liquidity for its near-term UGN-102 development. If all goes as hoped, UroGen will launch UGN-102 in Q1 2025. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
It's been a sad week for UroGen Pharma Ltd. ( NASDAQ:URGN ), who've watched their investment drop 20% to US$14.46 in...Analiz Makalesi • Jan 18
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 6.2x might make it look like a strong buy right...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$133m |
| Dec 31 2025 | US$4m | US$856k | -US$153m |
| Sep 30 2025 | n/a | n/a | -US$165m |
| Jun 30 2025 | n/a | n/a | -US$155m |
| Mar 31 2025 | n/a | n/a | -US$138m |
| Dec 31 2024 | US$4m | US$826k | -US$127m |
| Sep 30 2024 | n/a | n/a | -US$115m |
| Jun 30 2024 | n/a | n/a | -US$114m |
| Mar 31 2024 | n/a | n/a | -US$104m |
| Dec 31 2023 | US$5m | US$794k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$105m |
| Jun 30 2023 | n/a | n/a | -US$109m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$2m | US$764k | -US$110m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | -US$113m |
| Dec 31 2021 | US$4m | US$739k | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$117m |
| Dec 31 2020 | US$2m | US$637k | -US$128m |
| Sep 30 2020 | n/a | n/a | -US$137m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$121m |
| Dec 31 2019 | US$26m | US$695k | -US$105m |
Tazminat ve Piyasa: Liz 'ın toplam tazminatı ($USD 4.31M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.45M ).
Tazminat ve Kazançlar: Liz şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Liz Barrett (63 yo)
7.3yrs
Görev süresi
US$4,310,624
Tazminat
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 7.3yrs | US$4.31m | 0.67% $ 9.8m | |
| General Counsel | 5.8yrs | US$1.20m | 0.11% $ 1.5m | |
| Chief Medical Officer | 8.4yrs | US$1.17m | 0.28% $ 4.0m | |
| Chief Financial Officer | 1.6yrs | US$1.43m | 0.0047% $ 68.1k | |
| Senior Director of Investor Relations | no data | Veri yok | Veri yok | |
| Senior Vice President of Human Resources | less than a year | Veri yok | Veri yok | |
| Executive Vice President of Research & Development and Technical Operations | 6.2yrs | Veri yok | Veri yok | |
| Executive Vice President of Regulatory Affairs & Quality | 6.2yrs | Veri yok | Veri yok | |
| Chief Development Officer | 2.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Business Development & Portfolio Strategy | no data | Veri yok | Veri yok | |
| Advisor | no data | US$699.77k | Veri yok |
6.0yrs
Ortalama Görev Süresi
59yo
Ortalama Yaş
Deneyimli Yönetim: URGN 'un yönetim ekibi deneyimli ve deneyimlidir ( 6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 7.3yrs | US$4.31m | 0.67% $ 9.8m | |
| Independent Director | 8.6yrs | US$389.74k | 0.0041% $ 59.7k | |
| Independent Director | 10.4yrs | US$382.24k | 0.0041% $ 59.7k | |
| Independent Chairman | 13.4yrs | US$537.49k | 0.84% $ 12.2m | |
| Independent Director | 3.5yrs | US$396.27k | 0.0041% $ 59.7k | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Chairman of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 2.8yrs | US$383.22k | 0.0082% $ 119.5k | |
| Independent Director | 3.8yrs | US$392.24k | 0.0041% $ 59.7k |
7.3yrs
Ortalama Görev Süresi
68yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: URGN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 07:40 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
UroGen Pharma Ltd. 22 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Anita Dushyanth | Berenberg |
| Jason Kolbert | D. Boral Capital LLC. |
| Paul Choi | Goldman Sachs |